1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer
PHASE1
The goal of this part (Part 1) of this clinical research study is to learn ...
Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
PHASE2
This phase II trial tests the effect of intravesical nadofaragene firadenov...
Status
Not Yet Recruiting
Location
Fred Hutch/University of Washington Cancer Consortium